INCINTAS THERAPEUTICS, INC.
Unlocking the potential of successful pregnancy
in reproductive medicine
Infertility now effects one in six couples as the global population is in steep decline.
The need to improve pregnancy outcome in assisted reproduction has never been greater.
About Us
WHAT WE DO
"We intend to move the needle pretty far in assisted reproduction by mitigating the main hurdle in achieving pregnancy in IVF: failed implantation."
Incintas Therapeutics is comprised of an accomplished team of scientists, physicians, geneticists and business professionals who are determined to improve pregnancy outcome in reproductive medicine.
DISCOVERIES
- Receptivity within the uterus during IVF treatment only lasts for about 24 hours.* Compared to normal healthy pregnancy during which time the uterine lining is receptive for six days, this brief period of receptivity has created a fertility plateau of ~30% that has remained for several dacades.
- Embryonic implantation is concentration dependent; too little or too much progesterone within the uterine lining hinders pregnancy outcome.
- Incintas Therapeutics, Inc. identified the ideal endometrial Progesterone Concentration Range associated with 73-81% pregnancy rate which cannot be sustained using products currently available on today's market.
Why this happened?
For over four decades, clinicians have relied upon progesterone concentration
within a woman's bloodstream to identify uterine receptivity.
This improper assumption has misguided the entire field of assisted reproduction for decades.**
*ER-Map Studies, (Enciso, et.al., 2016, 2018)
**Measuring serum progesterone is not a reliable means of determining uterine receptivity,
(Labarta, 2021 and Lawrenz/Fatemi, 2024)
HOW INCINTAS MITIGATES THE FERTILITY PLATEAU:
Unlike all other IVF products on the market, Incintas figured out how to precisely modulate
uterine receptivity by administering progesterone within the uterus, directly upon the most receptive area where implantation actually occurs and pregnancy begins.
A novel patented intrauterine route of progesterone administration circumvents the woman's systemic circulation which cannot control the precise hormonal concentration at a molecular level.
Incintas has developed a targeted intrauterine time-released progesterone formulation to extend uterine receptivity up to five times longer than all conventional luteal phase support products currently on the market. This translates to higher likelihood of acheiving pregnancy in a couple's very first IVF or IUI treatment, eliminating the stress and cost for subsequent cycles.
